Skip to content

Corneal Endothelium After Phacoemulsification in Pseudo Exfoliation Syndrome

Corneal Endothelial Evaluation After Phacoemulsification in Eyes With Pseudoexfoliation Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05447130
Enrollment
40
Registered
2022-07-07
Start date
2019-03-01
Completion date
2020-12-31
Last updated
2022-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Endothelial Cell Loss, Pseudoexfoliation Syndrome

Keywords

corneal endothelial cell loss, pseudoexfoliation syndrome , cataract

Brief summary

To study corneal endothelial cells changes after phacoemulsification in patients with senile cataract and pseudoexfoliation syndrome (PEX) compared with control patients with senile cataract using specular microscope.

Detailed description

In a prospective interventional case-control study, 20 eyes with cataract and PEX and 20 control eyes with cataract without PXE were subjected to phacoemulsification and posterior chamber foldable intraocular lens implantation in Minia University Hospital and Genaidy Eye Center between March 2019 and December 2020. Specular microscopy was done preoperatively, 3 and 6 months postoperatively. Endothelium cell density (ECD), coefficient variation (CV), hexagonality, pleomorphism and corneal thickness were evaluated and compares between PXE and control eyes.

Interventions

PROCEDUREphacoemulsification

phacoemulsification with corneal endothelial evaluation by specular microscopy

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* senile cataract age more than 55 years

Exclusion criteria

* PEX with glaucoma, eyes with cornea guttata or any corneal dystrophy, zonular dehiscence, very dense nuclear cataract (cataracta nigra) history of previous ocular surgery.

Design outcomes

Primary

MeasureTime frameDescription
corneal endothelial cell loss6 monthscorneal endothelial cell loss

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026